You are here:

Archived: Valganciclovir (Valcyte)


Recommended for restricted use within NHS Scotland.


Valganciclovir offers a convenient oral alternative to ganciclovir. It is currently only licensed for the management of CMV retinitis in AIDS patients. Its use should be under the overall supervision of an expert ophthalmologist and a physician experienced in the management of HIV / AIDS patients.

Drug Details

Drug Name: Valganciclovir (Valcyte)
SMC Drug ID: 21/02
Manufacturer: Roche
Indication: Induction and maintenance treatment of cytomegalovirus (CMV) retinitis in patients with acquired immunodeficiency syndrome (AIDS).
BNF Category:
Sub Category: 5.3 Antiviral Drugs
Submission Type: Full submission
Status: Restricted
Date Advice Published: 6 December 2002

Current Advice

Abbreviated Submission 8 September 2003